Inhibition of PCAF histone acetyltransferase, cytotoxicity and cell permeability of 2-acylamino-1-(3-or 4-carboxy-phenyl)benzamides

Molecules

Volumn 17, Issue 11, 2012, Pages 13116-13131

  Park, Woong Jae ^a   Ma, Eunsook ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

2 acylaminobenzamide; Caco 2 cell permeability; Cytotoxicity; Histone acetyltransferase (HAT); P300 CBP associated factor (PCAF)

Indexed keywords

ANTHRANILIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; HISTONE ACETYLTRANSFERASE PCAF; P300-CBP-ASSOCIATED FACTOR;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IC 50; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; HUMANS; INHIBITORY CONCENTRATION 50; ORTHO-AMINOBENZOATES; P300-CBP TRANSCRIPTION FACTORS;

EID: 84870155994     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules171113116     Document Type: Article

References (32)

1. Biel, M.; Wascholowski, V.; Giannis, A. Epigenetics - an epicenter of gene regulation: Histones and histone-modifying enzymes. Angew. Chem. Int. Ed. Engl. 2005, 44, 3186-3216.
2. Feinberg, A.P.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301, 89-92.
3. Nakao, M. Epigenetics: Interaction of DNA methylation and chromatin. Gene 2001, 278, 25-31.
4. Hake, S.B.; Xiao, A.; Allis, C.D. Linking the epigenetic "language" of covalent histone modification to cancer. Br. J. Cancer 2004, 90, 761-769.
5. Inche, A.G.; La thangue, N.B. Chromatin control and cancer-drug discovery: Realizing the promise. Drug Discov. Today 2006, 11, 97-109.
6. Davis, C.D.; Ross, S.A. Dietary components impact histone modifications and cancer risk. Nutr. Rev. 2007, 65, 88-94.
7. Ghizzoni, M.; Boltjes, A.; de Graaf, C.; Haisma, H.J.; Dekker, F.J. Improved inhibition of the histone acetyl transferase PCAF by an anacardic acid derivative. Bioorg. Med. Chem. 2010, 18, 5826-5834.
8. Carrozza, M.J.; Utley, R.T.; Workman, J.L.; Cote, J. The diverse functions of histone acetyl transferase complexes. Trends Genet. 2003, 19, 321-329.
9. Sterner, D.V.; Berger, S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 2000, 64, 435-459.
10. Dekker, F.J.; Haisma, H.J. Histone acetyl transferases as emerging drug targets. Drug Discov. Today 2009, 14, 942-948.
11. Lau, O.D.; Kundu, T.K.; Soccio, R.E. HATs off: Selective synthetic inhibitors of the histone acetyltransferase p300 and PCAF. Mol. Cell 2000, 5, 589-595.
12. Balasubramanyam, K.; Altaf, M.; Varier, R.A.V.; Swaminathan, V.; Ravindran, A.; Sadhale, P.P.; Kundu, T.K. Polyisoprenylated benzophenone, Garcinol, A natural histone acetyltransferase inhibitor, Represses chromatin transcription and alters global gene expression. J. Biol. Chem. 2004, 279, 33716-33726.
13. Balasubramanyam, K.; Varier, R.A.; Altaf, M.V.; Swaminathan, V.; Siddappa, N.B.; Ranga, U.; Kundu, T.K. Curcumin, A novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, Represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279, 51163-51171.
14. Stimson, L.; Rowlands, M.G.; Newbatt, Y.M.; Smith, N.F.; Raynaud, F.I.; Rogers, P.; Bavetsias, V.; Gorsuch, S.; Jarman, M.; Bannister, A.; et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol. Cancer Ther. 2005, 4, 1521-1532.
15. Hemshekhar, M.; Santhosh, M.S.; Kemparaju, K.; Girish, K.S. Emerging roles of anacardic acid and its derivatives: A pharmacological overview. Basic Clin. Pharmacol. Toxcol. 2012, 110, 122-132.
16. Eliseeva, E.; Valkov, V.; Jung, M.; Jung, M.O. Characterization of novel inhibitors of histone acetyltransferases. Mol. Cancer Ther. 2007, 6, 2391-2398.
17. Souto, J.A.; Conte, M.; Alvarez, R.; Nebbioso, A.; Carafa, V.; Altucci, L.; Lera, A.R. Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities. ChemMedChem 2008, 3, 1435-1442.
18. Chandregowda, V.; Kush, A.; Reddy, G.C. Synthesis of benzamide derivatives of anacardic acid and their cytotoxic activity. Eur. J. Med. Chem. 2009, 44, 2711-2719.
19. Mantelingu, K.; Kishore, A.H.; Balasubramanyam, K.; Kumar, G.V.; Altaf, M.; Swamy, S.N.; Selvi, R.; Das, C.; Narayana, C.; Rangappa, K.S.; et al. Activation of p300 histone acetyltransferase by small molecules altering enzyme structure: Probed by surface-enhanced Raman spectroscopy. J. Phys. Chem. B 2007, 111, 4527-4534.
20. Sbardella, G.; Castellano, S.; Vicidomini, C.; Rotili, D.; Nebbioso, A.; Miceli, M.; Aitucci, L.; Mai, A. Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyl transferases. Bioorg. Med. Chem. Lett. 2008, 18, 2788-2792.
21. Green, I.R.; Tocoli, F.E.; Lee, S.H.; Nihei, K.; Kubo, L. Molecular design of anti-MRSA agents based on the anacardic acid scaffold. Bioorg. Med. Chem. 2007, 15, 6236.
22. Hird, N.W.; Milner, P.H. Synthetic and β-lactamase inhibition of anacardic acids and their analogues. Bioorg. Med. Chem. Lett. 1994, 4, 1423-1426.
23. Yamagiwa, Y.; Ohashi, K.; Sakamota, Y.; Hirakawa, S.; Kamikawa, T.; Kubo, I. Syntheses of anacardic acids and ginkgoic acid. Tetrahedron 1987, 43, 3387-3394.
24. Levin, J.I.; Turos, E.; Weinreb, S.M. An alternative procedure for the aluminium-medated conversion of esters to amides. Syn. Commun. 1982, 12, 989-993.
25. Gustafsson, T.; Ponten, F.; Seeberger, P.H. Trimethylaluminum mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral. Chem. Commun. 2008, 9, 1100-1102.
26. Sambuy, Y.; De Angelis, I.; Ranaldi, G.; Scarino, M.L.; Stammati, A.; Zucco, F. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 2005, 21, 1-26.
27. Azenha, M.A.; Evangelista, R.; Martel, F.; Vasconcelos, M.T. Estimation of the human intestinal permeability of butyltin species using the Caco-2 cell line model. Food Chem. Toxicol. 2004, 42, 1431-1442.
28. Artursson, P.; Palm, K.; Luthman, K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 1996, 22, 67-84.
29. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 1991, 175, 880-885.
30. Dekker, F.J.; Ghizzoni, M.; van der Meer, N.; Wisastra, R.; Haisma, H.J. Inhibition of the PCAF histone acetyltransferase and cell proliferation by isothiazolones. Bioorg. Med. Chem. 2009, 17, 460-466.
31. Trievel, R.C.; Li, F.Y.; Marmorstein, R. Application of a fluorescent histone acetyltransferase assay to probe the substrate specificity of human p300/CBP-associated factor. Anal. Biochem. 2000, 287, 319-328.
32. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bodesh, H.; Kenny, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.